Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2021 | Story Bulelwa Moikwatlhai | Photo Supplied
Ms. Mosa Moerane; UFS officer: Kovsie support services.


The COVID-19 pandemic has forced the world into a new normal, with no tips on how to navigate it, nor an end date in sight. We have all found ourselves learning, piloting, evaluating, and repeating the process. Fortunately, one can now say that we have somehow found a balance; however, in this balance, a lot of variables are emerging. One of these is how our diversity impacts the way we interact when we use virtual spaces. As a university, we serve people of diverse cultures daily – hence, as an office, we wanted to explore this variable further. Furthermore, as an institution of higher education, we have a responsibility to contribute knowledge about teaching and learning in virtual spaces.  

The purpose of the International Cultural Diversity Festival is to have intellectual engagements; to learn from experts as well as peers (educate); to teach one another (information sharing); to have social cohesion and to celebrate the diverse cultures through artistic expressions. All of this will be done under the theme ‘embracing diversity in virtual spaces.’ Some of the topics include practising cultural sensitivity; how to incorporate diversity, honour, respect, and your cultural background; social media communication with people of diverse cultures; the psychology of human behaviour and cross-cultural networking in virtual spaces; as well as how the UFS strives to embrace diversity in virtual spaces.

Date: 17 September 2021
Topic: Embracing diversity in virtual spaces
Time: 10:00
Venue: 2021 ICDF 

Facilitator: Ms Mosa Moerane

Panellists:

Prof Katherine Wimpenny
Professor of Research in Global Learning at Coventry University

Dr. Grey Magaiza
Head of Community Development at the UFS and Program Director in the Faculty of Humanities at the QwaQwa campus 

Ms. Reabetswe Mabine
Marketing and Communication strategist: UFS Postgraduate School

Mrs Bulelwa Moikwatlhai
Coordinator: Internationalisation at Home and Inbound Student Mobility

Biographies of panellist


Prof Katherine Wimpenny, PhD, leads the research theme ‘Global Education: Learning without Boundaries’ in the Research Institute for Global Learning, Coventry University, UK. Prof Wimpenny’s research focuses on contextualised and comprehensive internationalisation at the interface of decolonisation of education practices, embedded in the broader context of curriculum transformation. She is researching a diversity of learning spaces (digital – especially Collaborative Online International learning, face to face, blended, formal, and non-formal) that interweave to impact educational opportunities, which can serve to connect international learning communities, as well as to connect the university to its locale.  Prof Wimpenny has a substantial track record as principal and co-investigator on large-scale international education research projects and disseminates her work widely through a range of publications/media.

Dr Magaiza is a social scientist with an interest in community development, particularly participatory, bottom-up approaches to social change. He uses his interest in inclusive development approaches to not only theorise sustainable change, but also to critically reflect on the role of science and knowledge in community change. As a scholar of community development, he has used this knowledge with student structures such as Enactus to look for ways of using business principles to improve communities. Dr Magaiza is also coordinating the UK-USDP project that currently has 10 staff members enrolled as PhD students at the UFS, Univen, and the University of the Highlands and Islands in Scotland. 
 
He is currently the Head of Community Development at the UFS and Programme Director in the Faculty of the Humanities on the Qwaqwa Campus.

Being multi-faceted often makes it difficult to discover your voice and place in this fast-paced society; this is, however, not the case with Reabetswe Mabine – also known as Rea Mabine – who embodies authenticity and self-determinism. From pageantry to leadership and business, she positions herself as someone who is grounded and wants to achieve success on her terms. 
Rea Mabine is a marketing and communications strategist who runs a branding and marketing consultancy that helps start-ups and small businesses to launch and position their businesses competitively within their industries, using effective marketing and communication strategies as well as strategic brand development. 

- She is a friend of ‘The Network’ – a show on City Radio, which is an online radio station where she gives her expert opinion on topics about digital marketing, social media, and legal aspects in the marketing field. 
- She is the former Youth President of Phenomenal Women Youth Chamber of Commerce and Industry, an organisation aimed at encouraging entrepreneurship among young females in South Africa. 
- In 2018, she was recognised as Young Woman of Achievement by the Free State Heroines Awards Ceremony. This award recognises a young female who portrays outstanding involvement with youth-related initiatives and shows excellence in her pursuits. 
- She is a Play Your Part, Brand SA ambassador.
- Rea Mabine co-produced, co-directed, and co-presented a television show that aired on national TV and received an award for the best traditional TV programme at the nationally renowned South African Traditional Music Awards (SATMA). 
- Rea Mabine was a top-10 finalist for Miss Heritage South Africa in 2016, and the first-ever to be crowned Miss Heritage Free State.

Despite her achievements, she stays grounded and is always looking for the next challenge. Rea Mabine is also passionate about professional and career development for women; initiatives that empower women are very close to her heart.

Mrs Moikwatlhai is passionate about student life and integration; internationalisation; the development of students’ international and intercultural competencies, as well as ensuring that all UFS students have an international experience during their studies at the UFS. She achieves this by developing co-curricular activities that help to improve students’ experiences at the UFS. As the university’s expert on internationalisation at home, she uses her knowledge to improve first-year experiences in her capacity as a member of the UFS First-Year Experience (FYE) Committee. Mrs Moikwatlhai is also the university’s expert on student mobilities, coordinating and managing the UFS’ first virtual mobility programme. Additionally, she coordinates and manages the UFS’ flagship integration programme for local and international students in the Umoja Buddy Programme. 

She currently leads the University of the Free State Internationalisation at Home and Inbound Student Mobility portfolio in the Office for International Affairs.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept